MAY 2 1 2001 E

Attorney Docket No.: 5956.200-US.





## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Andersen et al.

Serial No.: 09/662,457

Group Art Unit: 1646

Filed: September 11, 2000

Examiner: To be assigned

Confirmation No: 9106

For: Modulators of Protein Tyrosine Phosphatases (PTPases)

#### **CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)**

Commissioner for Patents Washington, DC 20231

Sir:

I hereby certify that the attached correspondence comprising:

- 1. Request for Corrected Filing Receipt
- 2. Copy of Filing Receipt

is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents Washington, DC 20231

on 16 May 2001.

Sylvia Gonzalez

(name of person mailing paper)

(signature of person mailing paper)

Attorney Docket No.: 5956.200-US MAY 2 1 2001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE Ilication of: Andersen et al.

Application of: Andersen et al.

Serial No.: 09/662,457

Group Art Unit: 1646

Filed: September 11, 2000

Examiner: To be assigned

Confirmation No: 9106

For: Modulators of Protein Tyrosine Phosphatases (PTPases)

#### REQUEST FOR CORRECTED FILING RECEIPT

Commissioner for Patents Washington, DC 20231

Sir:

Applicants filed the above-captioned application on September 11, 2000.

The filing receipt received by Applicants incorrectly indicated that the city of residence for inventors Luke Milburn Judge is Seattle, Washington and inventor Barry Zvi Shapira is Acton, California. A copy of the filing receipt is attached to this request.

Applicants therefore request the issuance of a corrected filing receipt with complete information as to city of residence be revised to read Luke Milburn Judge, La Jolla, California and Barry Zvi Shapira, La Jolla, California.

Applicants submit that the error was the fault of the USPTO.

Date: 16 May 2001

Respectfully submitted,

Valeta A. Gregg, Reg. No. 35,127 Novo Nordisk of North America, Inc. 405 Lexington Avenue, Suite 6400


New York, NY 10174-6401

(212) 867-0123

PATENT TRADEMARK OFFICE

RECEIVE 1 of 4

AUG 1 3 2001



**CONFIRMATION NO. 9106** 

UPDATED FILING RECEIPT HIDDIN SIN DA HANDIN \*OC000000005980624\*

Steve T. Zelson, Esq. Novo Nordisk of North America Inc **Suite 6400** 405 Lexington Avenue New York, NY 10174-6401

Date Mailed: 04/18/2001

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the PTO processes the reply-to the Notice, the PTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

## Applicant(s)

Henrik Sune Andersen, Lyngby, DENMARK; Thomas Kruse Hansen, Herley, DENMARK; Jesper Lau, Farum, DENMARK; Niels Peter Hundahl Moller, Kobenhavn, DENMARK; Ole Hvilsted Olsen, Bronshoj, DENMARK; Frank Urban Axe, Escondido, CA; Yu Ge, San Diego, CA; Daniel Dale Holsworth, San Diego, CA; Todd Kevin Jones, Solana Beach, CA; Luke Milburn Judge, Seattle WA) La Jolla, CA William Charles Ripka, San Diego, CA; Barry Zvi Shapira, (Acton EA) La Jolla, CA. Roy Teruyuki Uyeda, San Diego, CA;

# Domestic Priority data as claimed by applicant

THIS APPLN CLAIMS BENEFIT OF 60/156,586 09/29/1999

## **Foreign Applications**

DENMARK PA 1999 01278 09/10/1999

If Required, Foreign Filing License Granted 10/30/2000

Projected Publication Date: N/A

Non-Publication Request: No

Early Publication Request: No

Title

Modulators of protein tyrosine phosphatases (PTPases)

**Preliminary Class** 

424

Data entry by : WOLDEYES, TEGUEST

Team : OIPE

Date: 04/18/2001

THE REAL PROPERTY OF THE PROPE

## LICENSE FOR FOREIGN FILING UNDER Title 35, United States Code, Section 184 Title 37, Code of Federal Regulations, 5.11 & 5.15

#### **GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CRF 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 36 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

### NOT GRANTED

No-license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15 (b).

# PLEASE NOTE the following information about the Filing Receipt:

- The articles such as "a," "an" and "the" are not included as the first words in the title of an application. They are considered to be unnecessary to the understanding of the title.
- The words "new," "improved," "improvements in" or "relating to" are not included as first words in the title of an application because a patent application, by nature, is a new idea or improvement.
- The title may be truncated if it consists of more than 600 characters (letters and spaces combined).
- The docket number allows a maximum of 25 characters.
- If your application was submitted under 37 CFR 1.10, your filing date should be the "date in" found on the Express Mail label. If there is a discrepancy, you should submit a request for a corrected Filing Receipt along with a copy of the Express Mail label showing the "date in."
- The title is recorded in sentence case.

Any corrections that may need to be done to your Filing Receipt should be directed to: